Holy Stone Healthcare, together with representatives of Holy Stone Biotech & MDT Int’l, will be exhibiting at 2016 BIO International Convention in USA. The event will be held from June 7th – 9th at Moscone Center, San Francisco.
Holy Stone Healthcare participates in the 4th Annual Biologics World Taiwan during February 25-26, 2016
Holy Stone Healthcare’s IBD98-M Approved for Phase IIa Clinical Trial in Italy.
Holy Stone Healthcare participates at 5th World Congress on Cancer Therapy during September 28-30 at Atlanta, Georgia, USA
2015 Bio International convention, Philadelphia, PA
HSHC presented two scientific posters at the 2014 ISSX / JSSX Joint Meeting, San Francisco, CA
Holy Stone Healthcare Receives FDA Approval to Initiate Phase 1 study of IBD98-M
Holy Stone Healthcare exhibited in 2014 BIO Conference
Good news comes in pairs for Holy Stone Healthcare! Holy Stone Healthcare’s Hsinchu Plant has passed GMP pilot plant evaluation, and “The new drug development plan of the new compound IBD98-M on inflammatory bowel diseases” was also granted subsidies after passing the review screening.